Guggenheim reiterated a Buy rating and $10.00 price target on Foamix Pharmaceuticals (NASDAQ: FOMX) following the company's 1Q earnings report ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE